市場調查報告書
商品編碼
1467688
2024-2032年嬰兒痙攣治療市場依治療類別、藥物類型(氨己烯酸、促腎上腺皮質激素等)、劑量、給藥途徑、配銷通路、最終用戶和地區Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type (Vigabatrin, Adrenocorticotropic Hormone, and Others ), Dosage, Route of Administration, Distribution Channel, End User, and Region 2024-2032 |
IMARC Group年,全球嬰兒痙攣症治療市場規模達36億美元。嬰兒癲癇發作的盛行率不斷上升、大眾健康意識的提高導致早期診斷、產品批准數量的增加和強大的管道藥物的存在是推動市場的一些關鍵因素。
嬰兒痙攣療法是指用於治療幼兒癲癇發作或癲癇症候群的治療程序,幼兒通常年齡在四個月到一歲之間。痙攣發作的特徵是身體突然僵硬,手臂、腿和頭部向前彎曲,背部拱起,以及短暫而微妙的癲癇發作。嬰兒痙攣症可由腦腫瘤、出生損傷、腦部感染和基因改變引起。針對嬰兒垃圾郵件有多種治療選擇,包括類固醇、促腎上腺皮質激素注射凝膠和糖皮質激素的荷爾蒙療法以及抗癲癇藥物。如果在痙攣發生後三週內實施,嬰兒痙攣症治療更有可能提供持續的結果,治療可以透過單一療法或合併療法來完成。嬰兒痙攣症可透過身體檢查、神經系統檢查、腦部 MRI 以及血液和尿液檢查來診斷。
新生兒中嬰兒痙攣症盛行率的增加是推動市場成長的重要因素。這可以歸因於全球出生率的大幅上升。與此一致的是,越來越多的產品批准和強大的管道藥物的存在正在對市場產生積極影響。嬰兒痙攣症治療的持續技術進步,例如引入用於檢測癲癇發作並提醒護理人員的癲癇警報裝置,正在為市場提供動力。此外,人們對早期診斷和治療的廣泛認知正在提高嬰兒痙攣症藥物的滲透率,從而推動市場成長。然而,各種因素,例如治療成功率較低、治療成本較高、藥物核准的嚴格規定以及未確診患者數量的增加,正在阻礙嬰兒痙攣症治療市場的成長。相反,一些國家的政府和私人組織為提高人們對醫療狀況的認知而採取的有利舉措和計劃正在創造積極的市場前景。主要市場參與者所進行的廣泛研發(R&D)活動進一步推動了市場的發展,這些活動專注於開發成功率更高的創新藥物。影響市場的其他一些因素包括不斷擴大的醫療保健支出、不斷增加的合作、夥伴關係和併購 (M&A)、快速城市化以及可支配收入水平的提高。
The global infantile spasms therapeutics market size reached US$ 3.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032. The rising prevalence of seizures in infants, increasing health consciousness among the masses resulting in early diagnosis, and the growing number of product approvals and presence of strong pipelines drugs represent some of the key factors driving the market.
Infantile spasms therapeutics refer to the treatment procedures used for treating seizures or an epilepsy syndrome in young children, usually aged between four months and a year of age. An episode of spasm is characterized by the body stiffening suddenly, arms, legs, and head bending forward, the back arching, and short, subtle seizures. Infantile spasm can be caused by brain tumors, birth injuries, infection of the brain, and genetic changes. There are a number of therapeutic options that are available for infantile spams, including steroids, hormone therapy with corticotropin injection gel and glucocorticoids, as well as antiseizure medications. Infantile spasms therapeutics are more likely to provide sustained results if they are implemented within three weeks after the spasms occur, and treatment can be done by monotherapy or combination therapy. Infantile spasms are diagnosed by physical examination, neurological examination, MRI of the brain, and blood and urine examinations.
The increasing prevalence of infantile spasms among newborn babies is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the birth rates across the globe. In line with this, the growing number of product approvals and presence of strong pipelines drugs are impacting the market positively. Continual technological advancements in the treatment of infantile spasms, such as the introduction of seizure alert device for detecting seizures and alerting the caregivers, are providing an impetus to the market. Also, the widespread awareness regarding early diagnosis and treatment is enhancing the penetration rate of infantile spasm drugs, thereby fueling the market growth. However, various factors, such as lesser treatment success rates, high cost of treatment, strict regulations for drug approval, and the augmenting undiagnosed patient pool, are impeding the growth of the infantile spasms therapeutics market. On the contrary, favorable initiatives and programs conducted by the government and private organizations of several countries for promoting awareness regarding the medical condition is creating a positive market outlook. The market is further driven by the extensive research and development (R&D) activities conducted by the key market players focusing on the development of innovative drugs with higher success rates. Some of the other factors contributing to the market include the expanding healthcare expenditure, rising number of collaborations, partnerships and merger and acquisitions (M&As), rapid urbanization, and inflating disposable income levels.
IMARC Group provides an analysis of the key trends in each segment of the global infantile spasms therapeutics market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on therapeutic class, drug type, dosage, route of administration, distribution channel, and end user.
Anticonvulsants
Corticosteroids
Others
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the therapeutic class. This includes anticonvulsants, corticosteroids, and others. According to the report, anticonvulsants represented the largest segment.
Vigabatrin
Adrenocorticotropic Hormone
Others (Phase III)
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the drug type. This includes vigabatrin, adrenocorticotropic hormone, and others (phase III). According to the report, adrenocorticotropic hormone represented the largest segment.
Solid
Liquid
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the dosage. This includes solid and liquid. According to the report, liquid represented the largest segment.
Oral
Parenteral
Others
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the route of administration. This includes oral, parenteral, and others. According to the report, parenteral represented the largest segment.
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the distribution channel. This includes hospital pharmacy, retail pharmacy, and online pharmacy. According to the report, hospital pharmacy represented the largest segment.
Hospitals
Clinics
Others
A detailed breakup and analysis of the infantile spasms therapeutics market based on the end user has also been provided in the report. This includes hospitals, clinics, and others. According to the report, hospitals accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for infantile spasms therapeutics. Some of the factors driving the North America infantile spasms therapeutics market include the presence of several key players, inflating disposable income levels, and the widespread awareness regarding early disease diagnosis and prevention.
The report has also provided a comprehensive analysis of the competitive landscape in the global infantile spasms therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.